Nice research report out on PRR's website. Doctor David Stanton of Nomura is probably Australia's best healthcare research analyst who has covered stocks of the likes of CSL,Resmed,Cochlear and started coverage on Mesoblast last year at $1.10. Now he has initiated a buy on Prima and if you look at the disclaimers the report there were no corporate fees attached to the report. This means PRR did not pay for this research report which is very rare.
Nomura even though out of Japan is the worlds largest securities trader in the world and with clients worldwide hopefully PRR can do a similar run to Mesoblast's after they initiated coverage on them at $1.10 and went all the way to $10.
Here is the link for those interested.
http://www.primabiomed.com.au/investor/analyst_reports_pdf/111102_nomura_initiantion.pdf
research report out
-
- There are more pages in this discussion • 71 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.020(6.45%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 31.5¢ | 28.0¢ | $2.100M | 7.109M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 233293 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 36945 | 2 |
View Market Depth
| Last trade - 16.10pm 02/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |